Irvine, Calif. – November 08, 2026 -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV), reported a statistically significant 42.4-point mean improvement in FACE-Q Satisfaction With Facial Appearance among 30 adults on GLP-1 medications who received combined neurotoxin and hyaluronic acid (HA) filler treatment. The result comes from HARMONY IN DIVERSITY, which the company describes as the first study of this combination in the GLP-1 population. Data from it and a second Phase 4 study, HALO, were presented at the American Society for Dermatologic Surgery (ASDS) Annual Meeting in San Diego, Nov. 5-8.
HARMONY IN DIVERSITY Cohort 2 links combined treatment to gains in skin quality and social function
Cohort 2 participants received HA injectables, onabotulinumtoxinA and a study-specified skincare regimen. The 42.4-point gain was measured from before treatment to 30 days after onabotulinumtoxinA treatment. Skin quality, psychological function and social function also improved significantly.
Most treatment-related adverse events were mild, nonserious and resolved without intervention. The company reported no evidence of distant spread of toxin.
HALO interim data show 95.7% of 25 patients felt they still looked like themselves
HALO evaluates HA injectables across the face in adults on stable GLP-1 doses. The interim analysis covered 25 of 75 participants to be treated. Mean FACE-Q Satisfaction With Facial Appearance rose 39.6 points from baseline to month 3.
In addition, 82.6% were satisfied or very satisfied with how natural they looked. On a SKIN-Q Looks item, 88% were satisfied with how natural their skin looks. Most treatment-related adverse events at the interim point were mild and nonserious.
Study design is open-label and single-arm, with no control group
Both studies are prospective, multicenter, open-label, single-arm Phase 4 trials using validated FACE-Q and SKIN-Q questionnaires, scored 0 to 100. HARMONY IN DIVERSITY enrolled 130 adults across 10 U.S. sites.
Joely Kaufman-Janette, M.D., a study investigator at Skin Research Institute, said population-specific data gives clinicians a clearer starting point for setting expectations. Darin Messina, Ph.D., AbbVie's senior vice president and head of aesthetics R&D, said the portfolio's breadth lets the company study its products in combination.
Cohort 1 of 100 participants across Fitzpatrick types I-VI records a 42.0-point gain
In the broader HARMONY IN DIVERSITY cohort, 100 participants aged 22-65 across Fitzpatrick skin types I-VI received multimodal treatment of the face and neck. They reported a statistically significant 42.0-point mean improvement in facial appearance satisfaction, plus gains in psychological and social function.
Allergan Aesthetics widens ASDS 2026 program to toxins, exosome serum and body contouring
An exploratory digital image analysis from a Phase 1 study found similar glabellar line severity and line detection assessments after investigational trenibotulinumtoxinE and BOTOX Cosmetic (onabotulinumtoxinA).
Four studies evaluated a topical serum containing exosomes derived from human fibroblasts. In a 12-week study of 36 premenopausal and postmenopausal women, the serum significantly improved skin tone evenness and smoothness by week 1 and lower facial sagging by week 8.
A separate presentation examined how treatment sequence affects outcomes and patient experience when combining cryolipolysis and electromagnetic muscle stimulation for abdominal body contouring.